School of Sociology and Population Studies, Renmin University of China, Beijing 100872, China.
Health Economics Unit, Department of Clinical Sciences, Malmö, Lund University, 22381 Lund, Sweden.
Int J Environ Res Public Health. 2020 Oct 7;17(19):7318. doi: 10.3390/ijerph17197318.
Using observational data to assess the treatment effects on outcomes of kidney transplantation relative to dialysis for patients on renal replacement therapy is challenging due to the non-random selection into treatment. This study applied the propensity score weighting approach in order to address the treatment selection bias of kidney transplantation on survival time compared with dialysis for patients on the waitlist. We included 2676 adult waitlisted patients who started renal replacement therapy in Sweden between 1 January 1995, and 31 December 2012. Weibull and logistic regression models were used for the outcome and treatment models, respectively. The potential outcome mean and the average treatment effect were estimated using an inverse-probability-weighted regression adjustment approach. The estimated survival times from start of renal replacement therapy were 23.1 years (95% confidence interval (CI): 21.2-25.0) and 9.3 years (95% CI: 7.8-10.8) for kidney transplantation and dialysis, respectively. The survival advantage of kidney transplantation compared with dialysis was estimated to 13.8 years (95% CI: 11.4-16.2). There was no significant difference in the survival advantage of transplantation between men and women. Controlling for possible immortality bias reduced the survival advantage to 9.1-9.9 years. Our results suggest that kidney transplantation substantially increases survival time compared with dialysis in Sweden and that this consequence of treatment is equally distributed over sex.
利用观察性数据评估接受肾移植治疗的患者相对于接受透析治疗的患者的治疗效果是具有挑战性的,因为这种治疗是基于非随机选择的。本研究应用倾向评分加权法来解决肾移植与透析治疗在等待名单上的患者的生存时间方面的治疗选择偏差。我们纳入了 1995 年 1 月 1 日至 2012 年 12 月 31 日期间在瑞典开始接受肾脏替代治疗的 2676 名成年患者。Weibull 和 logistic 回归模型分别用于结局和治疗模型。采用逆概率加权回归调整法估计潜在结局平均值和平均治疗效果。从开始肾脏替代治疗起的估计生存时间分别为肾移植 23.1 年(95%置信区间:21.2-25.0)和透析 9.3 年(95%置信区间:7.8-10.8)。与透析相比,肾移植的生存优势估计为 13.8 年(95%置信区间:11.4-16.2)。男性和女性之间的移植生存优势无显著差异。控制可能的不朽性偏差后,生存优势缩小至 9.1-9.9 年。我们的结果表明,在瑞典,与透析相比,肾移植显著增加了患者的生存时间,而且这种治疗效果在性别上分布均衡。